MNA在135至145买入、现报229，表现非常好，而向医疗保健的转型才刚刚开始；最近的催化剂是10月24日一场更新其癌症疗法3期数据的演示，财报则在11月6日。
逐段跳播
我们在 alpha 会员中做的买入之一就是 Mona。我们在190左右的热情消退后就在这里买入了。我们大约在这个区域，135到145买入的。现在它位于229。所以这是一个表现非常出色的标的。
不是所有东西都完美。但我要说，向医疗保健的转移我认为才刚刚开始。所以我会对此保持透明。
One of the buys that we made in the uh alpha membership is Mona. Uh and we bought this right here once the like 190 enthus enthusiasm faded. We bought this right around here like 135 to 145 in this region.
Uh it's now sitting at 229. So this is this is one that's doing really fantastically. Not everything does perfectly. But I will say it's it's been uh it's the the move to healthcare I think is just getting started too. So I'll be transparent about that.
Moerna 的财报什么时候发布？Mona 的财报将在11月6日发布。让我看看最近有没有关于 Mona 的消息。
when are Moerna earnings? Mona earnings are coming up on November 6th. Let me see if there's anything lately on Mona.
所以，我想看的是任何关于 Mona 的消息。我只是想调出 Mona 的资料。
So, what I want to see is anything on Mona. I'm just trying to pull up Mona.
人工智能的下一个板块可能就藏在眼皮底下。我们应该谈谈正在发生的一些突破，以及这个周六可能成为某只表现相当不错的股票另一个催化剂的事情。
The next sector for artificial intelligence might be hiding in plain sight. and we should talk about some of the breakthroughs that are going on as well as something happening this Saturday that could be another catalyst for a particular stock that's been doing pretty well.
我们在这里讨论的一切都与 AI 如何已经影响并将会影响医疗保健股票有关。我们在这里会提到的一些股票将是 Tempest AI、Mona 和 Eli Liy。
What we're talking about in this is everything to do with how AI is affecting already and going to affect healthc care stocks. Some of the stocks we'll touch on here are going to be Tempest AI, Mona, and Eli Liy.
现在，我想明确一点，在这三只中，我持有其中两只的仓位。首先要了解的是，Merna 这个周六有一场会议。那将是一场演示。他们特意选在市场休市的时候进行。演示将在10月24日举行。
这是最近的催化剂，也是关于其癌症疗法3期数据的最新进展，该疗法是
Now, I want to be clear out of these three, I've got exposure to two of them. So the first thing to know is that Merna has a meeting coming up this Saturday. Uh it is going to be a presentation.
They purposefully do it when the market is closed. Is going to be a presentation on October 24th. It's the nearest catalyst and it is an update on phase 3 data for their cancer therapy which is the